BCL2L1 and acute lymphoblastic leukemia: A multicenter retrospective cohort study compared the efficacy of VEN combined with chemotherapy to VEN combined with Navitoclax (a novel BCL-XL inhibitor) and chemotherapy in 11 R/R-T-ALL patients.